28 completed, 6 terminated, 5 unknown, 3 active not recruiting. 47 Phase 2, 6 Phase 1, 5 Phase 3.
Follow Mastocytosis: new trials by email Literature Review of Mastocytosis trials Research Report on Mastocytosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome Allogeneic CD34+-enriched and CD45RA-depleted PBSCs, Biospecimen Collection, Bone Marrow Aspiration - Acute Biphenotypic Leukemia, Acute Leukemia | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 52 | 2027-01-01 | 2026-09-14 |
| (Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis Bezuclastinib Tablets (Formulation A), Bezuclastinib Tablets (Formulation B), Placebo Tablets - SSM, Mastocytosis, Indolent | Phase 2 | Active not recruiting | Cogent Biosciences, Inc. | 237 | 2022-06-27 | 2026-10-22 |
| (HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis Elenestinib, Placebo - Indolent Systemic Mastocytosis, Smoldering Systemic Mastocytosis | Phase 2 / Phase 3 | Recruiting | Blueprint Medicines Corporation | 534 | 2021-11-30 | 2026-10-07 |
| (Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis bezuclastinib - Advanced Systemic Mastocytosis (AdvSM), SM With an Associated Hematologic Neoplasm (SM-AHN) | Phase 2 | Recruiting | Cogent Biosciences, Inc. | 140 | 2021-11-09 | 2026-09-15 |
| Hydroxychloroquine in Isolated Cutaneous Mastocytosis Patients or Indolent Systemic Mastocytosis With Associated Skin Involvement Patients Hydroxychloroquine - Mastocytosis | Phase 2 / Phase 3 | Unknown | University Hospital, Toulouse | 30 | 2021-10-01 | 2021-10-20 |
| Topical Composition Therapy for the Treatment of Cutaneous Mastocytosis Topical preparation of sodium cromolyn 5%, diphenhydramine 1% and trolamine salicylate 10% in emollient cream base. - Cutaneous Mastocytoses | Phase 2 | Terminated | Joseph Butterfield | 1 | 2021-07-26 | 2024-04-25 |
| COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 Vaccinations Moderna COVID-19 Vaccine, Pfizer-BioNTech COVID-19 Vaccine, Placebo - SARS-CoV Infection, COVID-19 | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 746 | 2021-04-07 | 2025-08-12 |
| Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis TL-895, Placebo - Myelofibrosis, Indolent Systemic Mastocytosis | Phase 2 | Unknown | Telios Pharma, Inc. | 121 | 2020-10-22 | 2024-05-10 |
| Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer Anti-CD123/CD3 Monoclonal Antibody MGD006 - Acute Biphenotypic Leukemia, Acute Leukemia | Phase 2 | Withdrawn | City of Hope Medical Center | 2020-10-20 | 2020-12-17 | |
| GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies GTB-3550 TriKE® Phase I, GTB-3550 TriKE® Phase II - High-risk Myelodysplastic Syndromes, Acute Myelogenous Leukemia | Phase 1 / Phase 2 | Terminated | GT Biopharma, Inc. | 12 | 2020-01-01 | 2022-11-10 |
| Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant Total-Body Irradiation, Thiotepa, Fludarabine - Acute Biphenotypic Leukemia, Acute Leukemia | Phase 2 | Active not recruiting | Fred Hutchinson Cancer Center | 45 | 2019-08-29 | 2026-09-25 |
| Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent Systemic Mastocytosis sarilumab, Placebo - Indolent Systemic Mastocytosis | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 21 | 2019-06-19 | 2024-12-17 |
| (PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis Avapritinib, Placebo - Indolent Systemic Mastocytosis | Phase 2 | Active not recruiting | Blueprint Medicines Corporation | 251 | 2019-04-16 | 2026-10-02 |
| (PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis Avapritinib - Advanced Systemic Mastocytosis, Aggressive Systemic Mastocytosis | Phase 2 | Completed | Blueprint Medicines Corporation | 107 | 2018-11-21 | 2026-10-20 |
| Treatment of Indolent Systemic Mastocytosis With PA101 PA101, Placebo - Mastocytosis, Systemic Mastocytosis | Phase 2 | Completed | Patara Pharma | 41 | 2015-06-01 | 2016-09-29 |
| Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis Ibrutinib - Aggressive Systemic Mastocytosis, Mast Cell Leukemia | Phase 2 | Terminated | Jason Robert Gotlib | 4 | 2015-03-01 | 2018-09-20 |
| Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia Brentuximab vedotin - Aggressive Systemic Mastocytosis, Mast Cell Leukemia | Phase 2 | Completed | Jason Robert Gotlib | 10 | 2013-09-01 | 2019-01-29 |
| Midostaurin in Indolent Systemic Mastocytosis Midostaurin, - Indolent Systemic Mastocytosis | Phase 2 | Unknown | University Medical Center Groningen | 20 | 2013-08-01 | 2015-01-19 |
| Cromoglicate in Mastocytosis Cromoglicate, Placebo - Mastocytosis | Phase 2 | Terminated | LEO Pharma | 7 | 2012-10-01 | 2025-02-24 |
| Cladribine Plus Pegylated Interpheron Alfa-2a in Systemic Mastocytosis Cladribine and pegylated interpheron alpha-2a - Systemic Mastocytosis | Phase 2 / Phase 3 | Unknown | Hospital Virgen de la Salud | 10 | 2012-05-01 | 2016-08-29 |
Showing 20 of 47. Sign in to see all of them.
Mastocytosis, Systemic (22) · Leukemia, Mast-Cell (21) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (14) · Leukemia, Myeloid, Acute (13) · Leukemia, Biphenotypic, Acute (11) · Leukemia, Myelomonocytic, Chronic (11) · Leukemia (10) · Burkitt Lymphoma (9) · Hodgkin Disease (9) · Leukemia, Hairy Cell (9) · Leukemia, Lymphocytic, Chronic, B-Cell (9) · Multiple Myeloma (9) · Myeloproliferative Disorders (9) · Lymphoma, B-Cell, Marginal Zone (8)
Neoplasms by Histologic Type (47) · Mast Cell Activation Disorders (46) · Neoplasms (46) · Immune System Diseases (45) · Neoplasms, Connective and Soft Tissue (35) · Neoplasms, Connective Tissue (34) · Hemic and Lymphatic Diseases (29) · Hematologic Diseases (27) · Leukemia, Myeloid (24) · Bone Marrow Diseases (19) · Leukemia (17) · Chronic Disease (16) · Disease Attributes (16) · Immunoproliferative Disorders (16)
Whole-Body Irradiation (5) · fludarabine phosphate (5) · Mycophenolic Acid (4) · Busulfan (3) · Cyclophosphamide (3) · Cyclosporine (3) · Peripheral Blood Stem Cell Transplantation (3) · fludarabine (3) · midostaurin (3) · Dasatinib (2) · Diphenhydramine (2) · Imatinib Mesylate (2) · Methotrexate (2) · Sodium Chloride (2) · Tacrolimus (2)
M.D. Anderson Cancer Center (5) · Fred Hutchinson Cancer Center (4) · Novartis Pharmaceuticals (4) · Blueprint Medicines Corporation (3) · Jason Robert Gotlib (3) · AB Science (2) · Asan Medical Center (2) · Cogent Biosciences, Inc. (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · City of Hope Medical Center (1) · Federico II University (1) · GT Biopharma, Inc. (1) · Hospital Virgen de la Salud (1) · JADO Technologies GmbH (1) · Joseph Butterfield (1)
United States (30) · Germany (12) · Italy (11) · France (10) · Netherlands (9) · Spain (9) · Australia (7) · Belgium (7) · Norway (7) · Poland (7) · United Kingdom (7) · Canada (6) · Switzerland (6) · Austria (5) · Denmark (4)
Srdan Verstovsek, MD (3) · Frank Siebenhaar, MD (2) · Jason Gotlib (2) · Kyoo H. Lee, MD (2) · Olivier Lortholary, MD, PhD (2) · Brenda Sandmaier (1) · Charles L. Loprinzi, M.D. (1) · David Maloney (1) · David Miklos (1) · Elizabeth C. Dees, MD (1) · Hagop M Kantarjian, MD (1) · Hirsh D Komarow, M.D. (1) · Ibrahim Aldoss, MD (1)
PMID 27355533, PMID 16775235, PMID 17715389, PMID 18327587, PMID 19451433, PMID 21098399, PMID 21108325, PMID 21523798, PMID 22563089, PMID 23547655, PMID 24057647, PMID 26002753, PMID 28744009, PMID 29890238, PMID 31350306, PMID 32437738, PMID 32499241, PMID 33049057, PMID 34663404, PMID 34873345, PMID 35640224, PMID 35790816, PMID 38320129, PMID 39649724, PMID 40529483, PMID 41244098, PMID 41604606, PMID 41690487
P30CA015704 (3), P01CA018029 (2), 2008 (1), 2017 (1), 2018 (1), N01CM62202 (1), P01CA049605 (1), P01CA078902 (1), P30CA015083 (1), P30CA124435 (1)